FDA approves Roche diagnostic for gene mutation in lung cancer
May 14, 2013 at 16:53 PM EDT
May 14 (Reuters) - U.S. health regulators on Tuesday approved a test developed by Roche for a specific gene mutation present in about 10 percent of non-small cell lung cancers, and said the company's drug Tarceva could be used as an initial treatment in patients with the mutation whose cancer has spread beyond the lungs.